Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized...

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (ERBB2)-negative advanced breast cancer (ABC) remains a significant clinical challenge, particularly after progression on endocrine therapy.
• Current treatment strategies aim to extend progression-free survival (PFS) and improve overall survival (OS) in this patient population.

Purpose of the Study:

• To evaluate the efficacy and safety of bireociclib plus fulvestrant compared to placebo plus fulvestrant in patients with HR-positive, ERBB2-negative ABC who progressed after endocrine therapy.
• To provide a final analysis of the BRIGHT-2 randomized clinical trial data, including extended follow-up.

Main Methods:

• A double-blind, placebo-controlled, phase 3 randomized clinical trial (BRIGHT-2) involving 305 patients in China.
• Patients received either bireociclib (360 mg orally every 12 hours) or placebo, in combination with fulvestrant (500 mg intramuscularly).
• The primary endpoint was investigator-assessed PFS; secondary endpoints included OS, objective response rate (ORR), duration of response, and safety.

Main Results:

• Bireociclib plus fulvestrant significantly prolonged median PFS (14.7 months vs. 7.3 months; hazard ratio, 0.54; P < .001) compared to placebo plus fulvestrant.
• The objective response rate was substantially higher in the bireociclib group (45.6% vs. 14.9%).
• Safety findings were consistent with interim analyses and known cyclin-dependent kinase 4/6 inhibitors, with manageable adverse events.

Conclusions:

• The final analysis of the BRIGHT-2 trial confirms that adding bireociclib to fulvestrant significantly improves PFS in patients with HR-positive, ERBB2-negative ABC after endocrine therapy progression.
• Bireociclib plus fulvestrant represents a viable treatment option with a manageable safety profile for this patient group.
• Consistent PFS benefits were observed across various subgroups, suggesting broad applicability of this combination therapy.